Authors

Jiankui Wang*, Yinqi Gao**, Linghai Zeng***, Yang Xu****, Zhiwei Huang#

Departments

*The 2nd Department of Breast Surgery, Breast Cancer Center of the Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, China - **Department of Breast, Capital Medical University Electric Power Teaching Hospital, Beijing, 100073, China - ***Department of Digestive Disease, the Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing 401120, China - ****Department of Integrated TCM & Western Medicine, The Third Hospital of Wuhan, Hubei wuhan, 430060, China

Abstract

Objective: To figure out the application values of human epididymis protein 4 (HE4) , cancer antigen 125 (CA125) and risk of ovarian malignancy algorithm (ROMA) in the diagnosis of the ovarian cancer. 

Methods: Enzyme-linked immunosorbent assay and enhanced chemiluminescence were adopted to measure the levels of HE4 and CA125 in serum of 103 ovarian cancer patients, patients with benign tumors in ovary and 100 healthy subjects. ROMA index was calculated based on the menopause of subjects.

Results: In the ovarian cancer group, levels of HE4 and CA125 in serum and ROMA index were (345.32±605.02) pmol/L, (701.45±1500.29) U/mL and (58.71±30.99) %, respectively; in benign tumor group, these were (53.83±14.67) pmol/L, (44.24±45.80) U/mL and (10.79±6.74) %, while in the healthy control group, these were (46.02±10.25) pmol/L, (17.38±10.63) U/mL and (6.91±3.84) %, respectively. Thus, the levels of HE4 and CA125 and the ROMA index in the ovarian cancer group outran those of the benign tumor group, with significant differences (P < 0.05). However, differences in HE4 levels and ROMA indexes between the healthy control group and the benign tumor group were not significant (P > 0.05), and significant difference was only found in CA125 levels (P < 0.05). Besides, for diagnosis of ovarian cancer, the sensitivities of levels of HE4 and CA125 and ROMA indexes were 71.84%, 76.70% and 89.32%, and specificities were 93.43%, 53.28% and 94.89%. We also identified that any increases in the clinical stage would come with elevations in the positive rates of HE4 and ROMA index: In Stage I, the positive rates of HE4 and ROMA index were 68% and 88%, all significantly lower than 92% of CA125. 

Conclusion: Combination of HE4, CA125 and ROMA index can increase the sensitivity and specificity in the diagnosis of the ovarian cancer. 

Keywords

Ovarian tumors, HE4, CA125, ROMA.

DOI:

10.19193/0393-6384_2020_3_278